Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant (RAD1901) FES-PET Imaging in Metastatic Breast Cancer
NCT02650817Phase 1Completed
- Sponsor
- Stemline Therapeutics
- Start
- Apr 2016
- Primary completion
- Aug 2018
- Modality
- Molecular Glues
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of elacestrant in breast cancer, sponsored by Stemline Therapeutics. Primary endpoint: Effect of ER Binding after RAD1901 treatment at 14 days. Started Apr 2016; status: completed.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02650817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650817.